Business Description

Description
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.
Name Current Vs Industry Vs History
Cash-To-Debt 0.21
Equity-to-Asset -6.19
Debt-to-Equity -0.43
Debt-to-EBITDA -0.39
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -95.03
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 15.3
3-Year EPS without NRI Growth Rate 12.1
3-Year FCF Growth Rate 29.7
Name Current Vs Industry Vs History
9-Day RSI 28.9
14-Day RSI 28.99
6-1 Month Momentum % -49.14
12-1 Month Momentum % -85.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.14
Quick Ratio 0.14
Cash Ratio 0.08
Days Sales Outstanding 249.36

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -75.3
Shareholder Yield % -391.55

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.28
EV-to-EBIT -0.41
EV-to-EBITDA -0.41
EV-to-Revenue 18.56
EV-to-FCF -0.63
Earnings Yield (Greenblatt) % -243.9
FCF Yield % -635.28